Hypril在中午增长了10％以上，创新的创新药物H1

HEPRUI ACTION（09989）的价格上涨了10.23％，达到7.11港元，售价为1.1亿港元。 On July 18, Hipre announced that the company developed independently an innovative drug candidate to inject H1710 (hereinafter, called "H1710") in Heparaase (HPA) and completed the first dose of its first patient in a clinical study of phase I. This progress marks an official entry in the clinical evaluation phase of the project, which represents a substantial step in the field of the innovative field on the innovative By HPA. 据报道，H1710是通过特殊肝素过程的设计和控制获得的活性抗凝肝素的衍生物。它具有更合理的链式长度和独特的灵活结构。它可以有效抑制肝素的活性和表达，并表现出抗肿瘤作用。迄今为止，基于全球营销的相同分子机制尚未批准类似的药物。 官方NINA Finance AC数数 24-最新信息和财务视频的流离失所，以及扫描QR码以关注更多粉丝（Sinafinance）